Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials.

Chinese clinical oncology - 1 Sept 2015

Alden Ryan S, Mandrekar Sumithra J, Oxnard Geoffrey R

Abstract excerpt

Genotype-directed targeted therapies have revolutionized the treatment of metastatic non-small cell lung cancer (NSCLC) but they have not yet been comprehensively studied in the adjuvant setting. Previous trials of adjuvant targeted therapy in unselected early stage NSCLC patients showed no benefit versus placebo, however retrospective data suggests improved disease free survival (DFS) with epidermal growth...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Lung Neoplasms

Share to Molecular Targeted Therapy

Share to Neoplasm Metastasis

Share to Protein Kinase Inhibitors

Share to Research Design

Source

Identifiers

PMID: 26408304
DOI: 10.3978/j.issn.2304-3865.2015.09.03

Genes

EGFR
ALK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials.PMID 26408304Read ↗

ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer.Semantic proximity Read ↗

ALCHEMIST: Bringing genomic discovery and targeted therapies to early-stage lung cancer.Semantic proximity Read ↗

Lung cancer genotype-based therapy and predictive biomarkers: present and future.Semantic proximity Read ↗

Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies.Semantic proximity Read ↗

Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come.Semantic proximity Read ↗

Role of genotyping in non-small cell lung cancer treatment: current status.Semantic proximity Read ↗

Power in numbers: meta-analysis to identify inhibitor-sensitive tumor genotypes.Semantic proximity Read ↗

The National Lung Matrix Trial of personalized therapy in lung cancer.Semantic proximity Read ↗

Pharmacogenetic Analysis of BR.21, a Placebo-Controlled Randomized Phase III Clinical Trial of Erlotinib in Advanced Non-small Cell Lung CancerSemantic proximity Read ↗

On the efficiency of targeted clinical trials.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.